Significance of Donanemab Versus Placebo in Alzheimer’s Disease Pathogenesis. A Systematic Review
Arid Barragán Ortíz, Marcos Arreola Flores, Christan J Monge Ortega, Sofia Andrade Lara, David A Chávez Castillo, Sergio M Carrillo Rodríguez, Thania F Estrada Ortega, Maria F Estrada Posadas, Gilberto Mauricio Suárez · 2025
Read Significance of Donanemab Versus Placebo in Alzheimer’s Disease Pathogenesis. A Systematic Review by Arid Barragán Ortíz, Marcos Arreola Flores, Christan J Monge Ortega, Sofia Andrade Lara, David A Chávez Castillo, Sergio M Carrillo Rodríguez, Thania F Estrada Ortega, Maria F Estrada Posadas, Gilberto Mauricio Suárez (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11712789.txt.
Description
Arid Barragán Ortíz and eight co-authors systematically reviewed the evidence on donanemab, an antibody drug for early Alzheimer disease. The drug targets a modified form of amyloid protein in brain plaques. The review gathers trial results, including the TRAILBLAZER-ALZ study, from searches of PubMed and the TRIP database.
Across studies, donanemab cleared plaque far beyond placebo, with scans showing a drop about 85 centiloid units larger at the main comparison. Patients on the drug also declined more slowly on a combined score of thinking and daily function over 76 weeks. Blood levels needed to stay above a threshold for plaque to keep falling. Side effects included the brain swelling and bleeding seen with this drug class. The authors judge donanemab a meaningful option for early disease while noting its risks.
Catalog record
| CREATOR | Arid Barragán Ortíz, Marcos Arreola Flores, Christan J Monge Ortega, Sofia Andrade Lara, David A Chávez Castillo, Sergio M Carrillo Rodríguez, Thania F Estrada Ortega, Maria F Estrada Posadas, Gilberto Mauricio Suárez |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |